The US pharmaceutical giant Pfizer sharply scaled back its earnings outlook for the year, blaming lower-than-expected sales of two drugs used to treat Covid-19, the company said Friday.
Earnings per share – the benchmark for the markets – should come in at between 1.45 and 1.65 dollars, compared with 3.25 to 3.45 dollars previously anticipated.“Full-year 2023 revenues for Paxlovid and Comirnaty are expected to be approximately $12.5 billion, a decline of $9.0 billion versus original expectations,” it added.
The company’s shares were more than three percent lower in after hours trading at 5:30pm local time in New York .Test positivity rates, hospitalizations and deaths due to the virus are all down over the last week, according to CDC data.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: